Zomedica Pharmaceuticals is a client of PCG Advisory, Inc., an investor relations and communications firm. Please see our disclosures in the research report as well as on our website www.pcgadvisory.com.
Learn More about Zomedica by gaining access to the latest Initiation report
PCG REPORT
Our pets mean the world to us, and for 9 out of every 10 Americans, they are just as much a member of our family as our siblings, parents, and children. Because of our enduring love for them, we do our best to provide great medical care, and the veterinary industry earns an incredible $50 billion dollars a year as a result.
When our pets do get sick, Zomedica plans to step in with innovative solutions, cutting-edge products, and teams who love their animals as much as the rest of us.
Want to learn more about Zomedica’s future plans? Download the Research Report on Zomedica to get extensive value on key investor areas, including clinical research reporting results
Zomedica is an industry-leading development-stage company, with plans to deliver solutions through a diverse pipeline of diagnostics and for companion animal conditions.
Home to a robust pipeline of animal diagnostics focused on developing solutions for previously unmet needs
Zomedica employs experienced doctors & veterinarians with decades of industry experience leading large cap companies.
Zomedica has an unrivaled market opportunity within the $2.6B global companion animal diagnostics market with that expected to grow at a CAGR of nearly 10% through 2024 to $10B and beyond.
TRUFORMA™ is Zomedica’s flagship product that is expected to launch in the near term alongside a digital customer data platform which will connect the line of products and the company’s diagnostic pipeline. The digital data platform will support veterinary teams with clinically relevant business services, including inventory management and key performance metrics.
TRUFORMA™ is used to detect thyroid & adrenal disorders in dogs and cats in as little as 15 minutes. It is comprised of a table-top instrument that uses disposable assay cartridges to test a range of samples including whole blood, serum, and plasma. Feasibility data has been achieved & recently completed the verification of TRUFORMA™ and the first assay.
TRUFORMA™ is expected to deliver several milestones, inclusive of product launch in select target markets, international expansion of TRUFORMA, and the marketing of two first-ever point-of-care assays
Zomedica Pharmaceuticals is a client of PCG Advisory, Inc., an investor relations and communications firm. Please see our disclosures in the research report as well as on our website www.pcgadvisory.com.
Zomedica is much like human diagnostic companies focusing on innovation, but unlike human pharmaceuticals have less red tape due to lesser FDA and governmental involvement which allows for shorter pipelines that are faster to market.
By focusing on an unmet need and creating real products backed by real data and validation of assays, Zomedica has a robust, diverse, and full pipeline that is ready to shake up an ever-growing industry.
Zomedica partnerships leverage relationships with Qorvo, Seraph Biosciences, and Celsee to advance products toward a global market opportunity.
Mr. Cohen is a seasoned medical device, pharmaceutical and biotechnology executive with a series of positions leading organizations with full P&L responsibility, and previous departmental management experience in virtually all functional areas, including international sales, R&D, healthcare services, M&A, corporate marketing, legal affairs and business & technology development, coupled with strategic oversight and planning positions.
Zomedica Pharmaceuticals is a client of PCG Advisory, Inc., an investor relations and communications firm. Please see our disclosures in the research report as well as on our website www.pcgadvisory.com.
Watch the video